Abstract
To explore the effects of azithromycin combined with budesonide and children's Chaiqiao Qingre granules on the efficacy and improvement of clinical symptoms of mycoplasma pneumonia in children. A retrospective analysis was conducted on the case data of 115 pediatric patients diagnosed with mycoplasma pneumonia admitted to our pediatric department between February 2023 and February 2024. Based on their treatment regimen, the patients were categorized into an observation group (OG) (treated with azithromycin in combination with budesonide and Xiao'er Chiqiao Qingre Granules, totaling 60 cases) and a control group (CG) (treated with azithromycin combined with budesonide, 55 cases). A comparative analysis was performed between the 2 groups regarding the total treatment effectiveness, duration until relief of clinical symptoms, alterations in immunoglobulin levels, pulmonary function indicators, serum C-reactive protein (CRP), serum procalcitonin (PCT) levels before and after treatment, and the incidence of adverse reactions. The total treatment effectiveness of OG markedly surpassed that of the CG (96.67% vs 80.00%) (P < .05), and the time for relief of various clinical symptoms in the OG (fever, cough, and pulmonary moist rales) was notably shorter (P < .05). After treatment, the levels of immunoglobulins, pulmonary function indicators, serum CRP, and serum PCT in both groups of children showed significant improvement compared to before treatment, but the improvement of OG was more significant compared to the CG (P < .05). There was no significant difference in the incidence of adverse reactions between the 2 groups of children (P > .05). Azithromycin combined with budesonide and children's Chaiqiao Qingre granules can effectively improve the clinical symptoms of children with mycoplasma pneumonia, enhance immune function, improve pulmonary function, reduce inflammatory response, and reduce the incidence of adverse reactions, which is worthy of clinical promotion and application.